DE

Preliminary Injunction confirmed by the German Federal Supreme Court in a Compulsory License Proceedings concerning a Medicament against AIDS

This is in follow up to our IP newsletter of September 1, 2016. As reported, an Isenbruck Bösl Hörschler LLP team headed by Fritz Lahrtz is currently representing the proprietor of a pharmaceutical patent together with attorneys-at-law of an internationally known German law firm in a preliminary injunction proceedings according to § 85 PatG concerning the request for a compulsory license according to § 24 PatG (German Patent Act). The matter in dispute concerns a medicament against AIDS.

In the recent hearing of July 11, 2017, the German Federal Supreme Court has decided to maintain the compulsory license granted provisionally be the German Federal Patent Court last year.

The oral hearing in the case on the merits will take place before the Federal Patent Court in November this year.

The reasons for the decision are not yet known, but with this confirmation, compulsory licenses now definitely represent a tool which should be considered when establishing the patent strategy for pharmaceutical products. Our Munich partner Fritz Lahrtz would be happy to answer any questions you may have if possible in view of the confidential parts of the case.

More articles from Dr. Raphael Bösl

The “Druckexemplar” determines the extend of protection conferred by a European patent

Dr. Raphael Bösl

Restoration of the Right of Priority under the PCT – different “Criterion for Restoration” before the USPTO and the EPO

Dr. Raphael Bösl

License Fees for a Compulsory License – Isentress II – German Federal Patent Court

Dr. Raphael Bösl

Follow-up: Preliminary Injunction confirmed by the German Federal Supreme Court in a Compulsory License Proceedings concerning a Medicament against AIDS

Dr. Raphael Bösl

Preliminary Injunction confirmed by the German Federal Supreme Court in a Compulsory License Proceedings concerning a Medicament against AIDS

Dr. Raphael Bösl

EPO clarifies practice in the area of plant and animal patents

Dr. Raphael Bösl

EPO stays all proceedings in which the invention is a plant or animal obtained by an essentially biological process

Dr. Raphael Bösl

Communication from the Chairmen of the UPC Preparatory Committee and the EPO Select Committee dealing with the Unitary Patent of July 1, 2016

Dr. Raphael Bösl

Functional Features – Essential Features: A New Perspective under Article 84 EPC

Dr. Raphael Bösl

Plant Patent Protection and Plant Variety Protection – Two Independent IP Rights?

Dr. Raphael Bösl

A pitfall to supplement information incorporated by reference under the EPC

Dr. Raphael Bösl

EPO: claims directed to the use of a product produced by a process

Dr. Raphael Bösl

Enlarged Board of Appeal of the EPO decided on Clarity – expected decision now issued (G 3/14)

Dr. Raphael Bösl

Deautomation is not per se Inventive – an Exemption from the Rule under the EPC

Dr. Raphael Bösl

Four Step Approach in Determining Sufficiency of Disclosure of a Parameter under the EPC

Dr. Raphael Bösl

Refocus on the Interpretation of “Undue Burden” for the Determination of the Scope of Protection under the EPC

Dr. Raphael Bösl

Functional Definition of Compounds in Use Claims – Different Decisions in Germany and “Europe”

Dr. Raphael Bösl